Lenalidomide 25mg
Product Overview
| Generic Name | Lenalidomide 25mg |
| Brand Name(s) | Revlimid® / Uldenaliv® |
| Category | Antineoplastic / Cancer |
| Form | 21 Oral Capsules |
| Strength | 25mg |
| Therapeutic Class | Immunomodulatory, antiangiogenic, antineoplastic agent. |
| ATC Code | L04AX04 |
Manufacturing & Regulatory
| Manufacturer | Celgene, BMS, Cipla |
| GMP Compliance | WHO-GMP, PIC/S-GMP |
| DMF/CEP | Type V DMF |
| COFEPRIS | 010.000.5619.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 5 units |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | SDS for antineoplastic/immunomodulatory oral solid |
| CTD Summary (PDF) | CTD proprietary; available under commercial agreement/license |
Special Notes
Lenalidomide is used in selected haematologic malignancies including multiple myeloma, myelodysplastic syndromes with del 5q, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma, depending jurisdiction and label.